ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
ATLANTA, May 03, 2017 -- Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the first quarter ended March 31, 2017, after the close of the financial markets on May 8, 2017.
An accompanying conference call will be hosted by Dan Myers, Chief Executive Officer and Rick Eiswirth, President and Chief Financial Officer to discuss the results. Management will also be joined by Dr. Christopher Riemann, volunteer professor at the University of Cincinnati department of ophthalmology and member of the board of directors of the Cincinnati Eye Institute to discuss his direct experience with patient outcomes and demand for ILUVIEN. The call will be held at 8:00 AM ET, on Tuesday, May 9, 2017. Please refer to the information below for conference call dial-in information and webcast registration.
Conference Details
Conference date: Tuesday, May 9th, 2017, 8:00 AM ET
Conference dial-in: 877-269-7756
International dial-in: 201-689-7817
Conference Call Name: Alimera Sciences' First Quarter 2017 Results Call
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.alimerasciences.com, under "Investor Relations".
About Alimera Sciences
Alimera Sciences, founded in June 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Alimera’s commitment to retina specialists and their patients is manifest in its product and development portfolio designed to treat early- and late-stage diseases. For more information, please visit www.alimerasciences.com.
Contact: CG Capital 877.889.1972 [email protected]
